Similar articles

• Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.

  Dunleavy K, Wilson WH. Dunleavy K, et al. Leuk Lymphoma. 2010 Sep;51(9):1583-4. doi: 10.3109/10428194.2010.508190. Leuk Lymphoma. 2010. PMID: 20795788 No abstract available.
• Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab.

  Halene S, Zieske A, Berliner N. Halene S, et al. Nat Clin Pract Oncol. 2006 Mar;3(3):165-8; quiz 169. doi: 10.1038/ncponc0430. Nat Clin Pract Oncol. 2006. PMID: 16520806
• Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment.

  Monjanel H, Hourioux C, Arbion F, Colombat P, Lissandre S, Regner MP, Senecal D. Monjanel H, et al. Leuk Res. 2010 Aug;34(8):e197-9. doi: 10.1016/j.leukres.2010.01.019. Epub 2010 Mar 7. Leuk Res. 2010. PMID: 20211489 No abstract available.
• Alemtuzumab in lymphoproliferate disorders.

  Dearden CE. Dearden CE. Rev Clin Exp Hematol. 2002 Dec;6(4):435-48; discussion 449-50. doi: 10.1046/j.1468-0734.2002.00308.x. Rev Clin Exp Hematol. 2002. PMID: 12823782 Review. No abstract available.
• The role of alemtuzumab in the management of T-cell malignancies.

  Dearden C. Dearden C. Semin Oncol. 2006 Apr;33(2 Suppl 5):S44-52. doi: 10.1053/j.seminoncol.2006.01.029. Semin Oncol. 2006. PMID: 16720203 Review.